Elite Pharmaceuticals Inc (OTCMKTS:ELTP) just announced its submission of an abbreviated new drug application (ANDA) for a generic version of extended-release oxycodone hydrochloride.
Some reading may already be familiar with this drug by way of its commercial name, OxyContin. Others may also be familiar with the difficulty that a number of other companies, most notably Epic Pharma, which was acquired by PuraCap back in March last year for around $550 million, had with their respective attempts to do what Elite is trying to do right now.
No comments:
Post a Comment